|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00173901 |
|
Date of registration:
|
12/09/2005 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Adverse Drug Reactions of Different Brands of Ceftazidime Injection
|
|
Scientific title:
|
Adverse Drug Reactions of Different Brands of Ceftazidime Injection |
|
Date of first enrolment:
|
March 2001 |
|
Target sample size:
|
536 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00173901 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
Taiwan
| | | | | | | |
|
Contacts
|
|
Name:
|
Shan-Chwen Chang, MD PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
National Taiwan University Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- patients in surgical intensive care unit who require ceftazidime treatment
Exclusion Criteria:
- less than 1 year old
Age minimum:
1 Year
Age maximum:
95 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Infection
|
|
Intervention(s)
|
|
Drug: ceftazidime
|
|
Primary Outcome(s)
|
|
The adverse drug reactions of ceftazidime
|
|
Secondary Outcome(s)
|
|
The effectiveness of ceftazidime
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|